Wednesday 16 March
09:00

"Wednesday 16 March"

Added to your list of favorites
Deleted from your list of favorites
PL3-1
09:00 - 10:30

Plenary Session
Gene-Based Therapy and Muscular Dystrophies

Moderators: Nathalie GOEMANS (B, Belgium), Carole VUILLEROT (MD) (Bron, France)
09:00 - 09:30 Advanced oligonucleotide therapeutics for neuromuscular disease. Matthew WOOD (Professor of Neuroscience) (Keynote Speaker, Oxford, United Kingdom)
09:30 - 10:00 Tricyclo-DNA: highly promising antisense oligonucleotides for splice switching therapeutic approaches. Aurelie GOYENVALLE (Scientist/Chair of Excellence HandiMedEx) (Keynote Speaker, Montigny Le Bretonneux, France)
10:00 - 10:30 AAV vectors as potential therapeutics for Duchenne Muscular Dystrophy. Caroline LE GUINER (Senior Scientist) (Keynote Speaker, Nantes, France)
Auditorium Lumière
10:30

"Wednesday 16 March"

Added to your list of favorites
Deleted from your list of favorites
CB3-1
10:30 - 11:00

Coffee break and exhibition (posters/stands)

11:00

"Wednesday 16 March"

Added to your list of favorites
Deleted from your list of favorites
SY3-1
11:00 - 12:30

Symposium
Parallel Symposium LGMD

11:00 - 11:30 #3017 - A mutation in the cAMP-binding domain of POPDC1 is causing a limb-girdle muscular dystrophy and cardiac arrhythmia.
A mutation in the cAMP-binding domain of POPDC1 is causing a limb-girdle muscular dystrophy and cardiac arrhythmia.

The Popeye domain containing 1 (POPDC1) gene encodes a plasma membrane-localized cAMP binding protein. Despite its essential role in regulating the structure and function of cardiac and skeletal muscle in animal models, this gene has never been associated with human cardiac and muscular diseases. We describe a homozygous missense variant (c.602C>T, p.S201F) in POPDC1, identified by whole exome sequencing, in a family-of-four with cardiac arrhythmia and mild limb girdle muscular dystrophy (LGMD). This very rare allele variation was absent in databases, and segregated with the phenotype. Further screening in 104 unrelated patients affected with cardiac rhythm disturbance and mild limb girdle myopathy or high CK resulted negative for other homozygous/compound heterozygous variations, which is consistent with a very rare, family-specific mutation. In skeletal muscle biopsies of two patients, the membrane levels of POPDC1S201F and of the related POPDC2 protein were reduced suggesting impaired membrane trafficking. The mutant protein displayed a 50% reduction in cAMP affinity and displayed deregulation of TREK-1 ion channel gating when injected into Xenopus oocytes. Forced expression of POPDC1S201F in HL-1 cells increased hyperpolarization and upstroke velocity of the action potential. The homologous mutation in zebrafish (popdc1S191F) displayed heart and skeletal muscle phenotypes, which resembled those observed in patients and also affected membrane trafficking. In addition, we showed that POPDC1 interacts with Caveolin 3, acting on membrane compartmentalization and with dystrophin and dysferlin, underlining the common functional circuits these proteins are involved in. Our study therefore identifies POPDC1 as a novel disease gene causing a very rare autosomal recessive cardiac arrhythmia and mild limb girdle muscular dystrophy. POPDC1 expands the heterogeneous genetic landscape of LGMDs with heart disturbances and opens novel pathways underling these complex genetic disorders. We are currently searching  for mutations in POPDC1 gene in other LGMD phenotypes in order to evaluate its causative role also as possible disease modifier.


Roland F.r. SCHINDLER, Chiara SCOTTON, Jianguo ZHANG, Rachele ROSSI, Chiara PASSARELLI, Beatriz ORTIZ-BONNIN, Subreena SIMRICK, Thorsten SCHWERTE, Kar-Lai POON, Mingyan FANG, Susanne RIENNÉ, Alexander FROESE, Viacheslav O. NIKOLAEV, Christiane GRUNERT, Thomas MULLER, Giorgio TASCA, Padmini SARATHCHANDRA, Fabrizio DRAGO, Bruno DALLAPICCOLA, Claudio RAPEZZI, Eloisa ARBUSTINI, Francesca Romana DI RAIMO, Marcella NERI, Francesca GUALANDI, Fabiana FATTORI, Antonello PIETRANGELO, Wenyan LI, Hui JIANG, Xun XU, Enrico BERTINI, Niels DECHER, Jun WANG, Thomas BRAND (Harefield, United Kingdom), Alessandra FERLINI
11:30 - 12:00 Trial readiness for patients with limb girdle muscular dystrophy. Volker STRAUB (Keynote Speaker, Newcastle, United Kingdom)
12:00 - 12:30 AAV-mediated transfer of FKRP shows therapeutic efficacy in a murine model of limb-girdle muscular dystrophy type 2i, but requires tight control of gene expression. Isabelle RICHARD (Researcher) (Keynote Speaker, EVRY, France)
Auditorium Pasteur

"Wednesday 16 March"

Added to your list of favorites
Deleted from your list of favorites
SY3-2
11:00 - 12:30

Symposium
Parallel Symposium Myotonic Dystrophies

11:00 - 11:30 Staufen1 Acts as a Disease Modifier in DM1. Bernard JASMIN (Keynote Speaker, Ottawa, Canada)
11:30 - 12:00 Neutralize RNA toxicity induced by expanded-CUG repeats in Myotonic Dystrophy. Denis FURLING (CNRS Research Director) (Keynote Speaker, Paris, France)
12:00 - 12:30 Structuring translational research in myotonic dystrophy: current approaches towards novel therapies. Guillaume BASSEZ (Keynote Speaker, Créteil, France)
Auditorium Lumière
12:30

"Wednesday 16 March"

Added to your list of favorites
Deleted from your list of favorites
LB3-1
12:30 - 14:30

Lunch and Exhibition
F. HOFFMANN - LA ROCHE Symposium

14:30

"Wednesday 16 March"

Added to your list of favorites
Deleted from your list of favorites
PL3-2
14:30 - 16:00

Plenary Session
Pharmacotherapy

Moderators: Bernard BRAIS (Co-Directeur) (Montreal, Canada), Urs RUEGG (Professor) (Geneva, Switzerland)
14:30 - 15:00 Pharmacotherapy of Duchenne muscular dystrophy: an overview on nutraceuticals and repurposed drugs. Olivier DORCHIES (Senior Researcher) (Keynote Speaker, Geneva, Switzerland)
15:00 - 15:30 Intravenous trehalose improves dysphagia and muscle function in oculopharyngeal muscular dystrophy (OPMD): preliminary results of 24 weeks open label phase 2 trial. Zohar ARGOV (Keynote Speaker, Jerusalem, Israel)
15:30 - 15:45 GNE myopathy – mechanism and therapy. Ichizo NISHINO (Director) (Keynote Speaker, Tokyo, Japan)
15:45 - 16:00 #3255 - A first clinical trial in SEPN1-related myopathy: the SELNAC study.
A first clinical trial in SEPN1-related myopathy: the SELNAC study.

SEPN1-Related Myopathy (SEPN1-RM) is a congenital muscle disease due to mutations of the SEPN1 gene, encoding selenoprotein N (SelN). SEPN1-RM is characterized by a relatively preserved ambulation, contrasting with severe trunk muscle weakness that can lead to death due to respiratory failure. No treatment is currently available, and clinical trial readiness in SEPN1-RM has been so-far hindered by the lack of sensitive and reliable biomarkers and outcomes.

We have shown previously that SelN is implicated in redox homeostasis, and that the antioxidant N-acetylcysteine (NAC) restores the phenotype in cultured cells from SelN-devoid patients. Recently, a preclinical study using the sepn1 KO mouse line allowed us to: i) describe so-far unknown phenotypical abnormalities which represent measurable outcomes; ii) identify muscle and systemic biomarkers iii) confirm the therapeutic efficiency of NAC in vivo in this SEPN1-RM model; iv) validate an optimum dose/effect.

Based on the results above, which improved dramatically clinical trial readiness in SEPN1-RM, we have designed the first trial in this rare condition. Given that this is a rare disorder and that there is no data about NAC use in human SEPN1-RM patients, we decided to start with a phase II-III pilot trial (SELNAC) which will take place at the Raymond Poincaré Hospital (URC Paris-Ouest, France). The SELNAC study is a randomized, double-blind, placebo-controlled cross-over trial which will include 24 adult patients (age: 18-60 years) with known SEPN1 mutations, and 24 healthy controls. We will measure the biological and functional response to NAC, including quantification of biomarkers, body mass and motor and respiratory function studies.

Thus, the SELNAC trial will use a safe, available and inexpensive drug to treat an incurable genetic disease. This study represents the first clinical trial in SEPN1-RM, and also the first drug treatment targeting a primary pathophysiological mechanism in a congenital myopathy.


Corinne DILL, Hélène PRIGENT, Anthony BÉHIN, Fiorella PIEMONTE, Enrico BERTINI, David ORLIKOWSKI, Brigitte ESTOURNET, Ana FERREIRO (PARIS)
Auditorium Lumière
16:00

"Wednesday 16 March"

Added to your list of favorites
Deleted from your list of favorites
CB3-2
16:00 - 16:30

Coffee break and exhibition (posters/stands)

16:30

"Wednesday 16 March"

Added to your list of favorites
Deleted from your list of favorites
SY3-3
16:30 - 18:00

Symposium
Parallel Symposium Inflammatory Myopathies

16:30 - 17:00 Recent progress in classification, clinical outcome definitions and treatments for idiopathic inflammatory myopathies. Olivier BENVENISTE (Keynote Speaker, Paris, France)
17:00 - 17:30 Immune-mediated necrotizing myopathy. Andrew MAMMEN (Keynote Speaker, Bethesda, USA)
17:30 - 18:00 Inclusion body myositis – current status. Ichizo NISHINO (Director) (Keynote Speaker, Tokyo, Japan)
Auditorium Pasteur

"Wednesday 16 March"

Added to your list of favorites
Deleted from your list of favorites
SY3-4
16:30 - 18:00

Symposium
Parallel Symposium FSHD

16:30 - 17:00 Are FSHD1 and FSHD2 merging diseases ? Sabrina SACCONI (Keynote Speaker, NICE, France)
17:00 - 17:30 Epigenetic derepression of DUX4 in FSHD. Silvère VAN DER MAAREL (Professor of Medical Epigenetics) (Keynote Speaker, Leiden, The Netherlands)
17:30 - 18:00 Phenotypic and molecular characterization of FSHD families: a systematic approach towards trial readiness. Rossela TUPLER (Keynote Speaker, Worcester, USA)
Auditorium Lumière